Chronic HCV infection associated with subtype 1b: assessment of the prevalence and nature of the course of secondary latent infection after primary interferon-free therapy

1. Sulima D.L., Suleymanova S.S., Yakovlev A.A. Virological failures of primary interferon-free therapy in patients with chronic HCV RNA viremia and successful repeated interferon-free therapy. HIV infection and immunosuppression, 2022, Vol. 14, No. 3, pp. 100–109 (In Russ.). https://doi.org/10.22328/2077-9828-2022-14-3-100-109.

2. Постерный доклад на WIDC Barselona 2022 (World Infectious Diseases Congress) / D.L.Sulima, S.S.Suleymanova, A.A.Yakovlev et al. The first experience in Russia of using off-label use of the GLE/PIB+SOF regimen for the treatment of a patient with relapse of HCV RNA subtype 1b viremia and RAS R117H in the NS3 region after NS3/4A PI+NS5Ai+NS5Bi-failure of the primary 3D-mode PTV/r/OBV+DSV (case report).

3. Yakovlev A., Sulima D., Larionov V. et al. Aviraemic low-level HCV RNA replication in PBMC/WBC as one of the results of primary interferon-free DAA therapy in real clinical practice in AVT-naive patients with chronic HCV RNA viremia (description case series). Doctor, 2020, Vol. 31, No 2, pp. 57–64 (In Russ.). https://doi.org/10.29296/25877305-2020-02-13.